Arrowsmith Accelerates Engineered Phage Therapy Development with Major Financing and FDA Support

-

As antimicrobial resistance continues to rise worldwide, bacteriophage therapy is increasingly emerging as one of the most promising alternatives to conventional antibiotics. In Japan, biotechnology company Arrowsmith has recently announced two important milestones that illustrate the growing maturity of the field: the successful completion of a Series A financing round totaling 1.05 billion yen and the completion of a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its lead phage therapy candidate, ARW001.

The Phage Therapy ©

The financing, equivalent to approximately 7.3 million US dollars, will primarily support the clinical development of ARW001, a therapeutic phage cocktail targeting Pseudomonas aeruginosa. This opportunistic Gram-negative bacterium is one of the most problematic hospital pathogens worldwide. It is responsible for severe respiratory infections, bloodstream infections, chronic wound infections and complications in patients with cystic fibrosis. Its exceptional capacity to acquire antibiotic resistance and to form protective biofilms has made it one of the priority pathogens identified by the World Health Organization.

ARW001 has been specifically designed to overcome these challenges. Rather than relying on a single bacteriophage, the therapy combines several phages selected for their broad host range and strong bactericidal activity. More importantly, Arrowsmith has developed a proprietary synthetic modification technology allowing phages to recognize alternative bacterial receptors. This engineering strategy expands the spectrum of susceptible clinical isolates and may help overcome one of the major limitations of natural phage therapy, namely the narrow host range of individual phages.

The company also reports that ARW001 incorporates functional genes that facilitate biofilm degradation. This feature is particularly relevant because biofilms represent one of the main barriers to successful treatment of chronic Pseudomonas infections. These highly structured bacterial communities can be several hundred micrometers thick and significantly reduce antibiotic penetration. Bacteria embedded within biofilms often exhibit antimicrobial tolerance levels hundreds or even thousands of times greater than planktonic cells, making infections extremely difficult to eradicate.

An important regulatory milestone was reached when Arrowsmith held a pre-IND meeting with the FDA regarding future clinical development in the United States. According to the company, the agency confirmed the adequacy of the planned clinical trial design, the preclinical package and the chemistry, manufacturing and controls strategy. Notably, the development pathway does not appear to require major additional toxicology studies under Good Laboratory Practice conditions, allowing the company to maintain its original timeline toward IND submission and the initiation of first-in-human clinical studies during 2026.

The announcement reflects a broader transformation occurring in phage therapy. Historically, therapeutic phages were isolated directly from the environment and administered with minimal modification. Modern approaches increasingly view phages as programmable biological platforms that can be engineered to expand host range, improve stability, degrade biofilms or deliver additional antibacterial functions. This convergence of synthetic biology and phage research is opening new possibilities for combating multidrug-resistant infections.

The investment round, supported by JAFCO, JIC Venture Growth Investments, ANRI and DBJ Capital, also highlights the growing confidence of investors in phage-based therapeutics. As antimicrobial resistance is projected to become one of the leading causes of mortality worldwide in the coming decades, innovative approaches such as engineered phage therapy are attracting increasing scientific, regulatory and financial attention.

With ARW001 and additional pipelines under development, Arrowsmith aims to contribute to the next generation of precision antimicrobials. While important clinical challenges remain, the combination of engineered phages, biofilm-targeting strategies and regulatory progress suggests that phage therapy is steadily moving closer to mainstream clinical practice.


Source : https://arrowsmith.co.jp/jp

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more